Telix Pharmaceuticals Limited (TLX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Telix Pharmaceuticals Limited (TLX) Healthcare & Pipeline Overview

Telix Pharmaceuticals Limited, headquartered in Australia, is a commercial-stage biopharmaceutical company specializing in therapeutic and diagnostic radiopharmaceuticals. It focuses on developing and commercializing innovative treatments for cancer and rare diseases across key markets including the US, Europe, and Asia, leveraging its advanced pipeline and existing commercial products like Illuccix.

What Is the Investment Thesis for TLX?

Telix Pharmaceuticals Limited presents a research focus on its commercial-stage operations and a robust pipeline in radiopharmaceuticals for cancer and rare diseases. The company's existing commercial product, Illuccix for prostate cancer, provides a revenue base, evidenced by a gross margin of 50.8%. While the company currently reports a profit margin of -0.9%, indicating ongoing investment in research and development and commercial expansion, the breadth of its pipeline suggests future revenue potential. Key value drivers include the successful progression of candidates like TLX250-CDx for renal cancer and TLX101-CDx for brain cancer through clinical trials and regulatory approval processes. The company's strategic focus on both diagnostic and therapeutic radiopharmaceuticals offers a differentiated approach in the oncology market. With a market capitalization of $4.03B and a beta of 0.65, Telix exhibits lower volatility compared to the broader market, which may appeal to certain investor profiles. Future growth catalysts are tied to new product launches, expanded market penetration for existing products, and positive data readouts from its diverse pipeline.

Based on FMP financials and quantitative analysis

TLX Key Highlights

Market capitalization stands at $4.03B, reflecting the company's valuation in the biopharmaceutical sector.

• Gross margin of 50.8% demonstrates strong profitability on products sold, indicating efficient production and pricing strategies for its radiopharmaceuticals.
• Profit margin of -0.9% indicates the company is currently investing heavily in R&D and commercial expansion, typical for a growth-oriented biopharmaceutical firm with an extensive pipeline.
• A Beta of 0.65 suggests lower volatility relative to the overall market, potentially offering a more stable investment profile within the often-volatile biotechnology industry.
• The company does not pay a dividend, consistent with a growth-focused strategy of reinvesting earnings into pipeline development and commercialization efforts.

Who Are TLX's Competitors?

TLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TLX's Key Strengths?

Commercial-stage presence with an approved product (Illuccix) generating revenue.

• Extensive and diverse pipeline of diagnostic and therapeutic radiopharmaceuticals for various cancers.
• Global operational footprint across Australia, Belgium, Japan, Switzerland, and the United States.
• Specialized expertise in the complex field of radiopharmaceutical development and manufacturing.

What Are TLX's Weaknesses?

Currently operating with a negative profit margin, indicating ongoing reliance on investment for growth.

• High R&D costs inherent in biopharmaceutical development, particularly for complex radiopharmaceuticals.
• Dependence on successful clinical trial outcomes and regulatory approvals for pipeline candidates.
• Potential challenges in scaling manufacturing and distribution for radiopharmaceuticals due to their short half-lives.

What Could Drive TLX Stock Higher?

TLX catalyst: Regulatory decisions for TLX250-CDx in renal cancer are anticipated, potentially leading to market authorization and new revenue streams beyond 2026.

• Positive clinical trial data readouts for TLX101-CDx/TLX101 in brain cancer, which could accelerate development and attract further investment or partnerships.
• Continued expansion of Illuccix's market penetration and adoption in existing territories, driven by increased physician awareness and favorable reimbursement policies.
• Initiation of new pivotal clinical trials for advanced pipeline candidates, such as TLX591 or TLX592 for prostate cancer therapy, signaling progress towards commercialization.
• Strategic partnerships or collaborations to enhance the development, manufacturing, or commercial reach of Telix's radiopharmaceutical portfolio in new geographic markets.

What Are the Key Risks for TLX?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Rich valuation — a P/E of 113.39 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.
• Clinical trial failures or unexpected adverse events for pipeline candidates like TLX250-CDx or TLX101-CDx could significantly delay or halt their development and commercialization.
• Intense competition in the oncology market, particularly from large pharmaceutical companies with established sales forces and broader product portfolios, could impact market share and pricing power.
• Regulatory hurdles and delays in obtaining marketing approvals for new radiopharmaceutical products in various jurisdictions, which could extend time-to-market and increase development costs.
• Manufacturing and supply chain complexities inherent to radiopharmaceuticals, including the need for specialized facilities, short half-lives of isotopes, and secure distribution networks.
• Intellectual property challenges, including patent disputes or the emergence of competitive technologies, could erode Telix's market position and future revenue potential.

What Are the Growth Opportunities for TLX?

• **Expansion of Illuccix Market Penetration:** Illuccix, Telix's commercial product for prostate cancer imaging, has significant potential for increased market penetration in existing geographies like the US, Australia, and Europe. The global prostate cancer diagnostic market is substantial, driven by an aging population and increased screening. As of 2026, continued physician education, expanded insurance coverage, and broader adoption in clinical guidelines could drive higher utilization rates. Telix aims to capture a larger share of this market by demonstrating superior diagnostic accuracy and patient outcomes, positioning Illuccix as a standard of care for specific prostate cancer indications.
• **Advancement of TLX250-CDx for Renal Cancer:** The development and commercialization of TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer represents a significant growth opportunity. Renal cell carcinoma is a challenging cancer with a need for improved diagnostic and therapeutic options. The global renal cancer market is projected to grow, with a particular emphasis on targeted therapies. Successful progression of TLX250-CDx through late-stage clinical trials and subsequent regulatory approvals would open up a new, substantial revenue stream for Telix, addressing both diagnostic imaging and targeted therapy for clear cell renal cell carcinoma.
• **Development of TLX101-CDx/TLX101 for Brain Cancer:** Telix's pipeline includes TLX101-CDx for brain (glioma) cancer diagnosis and TLX101 for glioblastoma treatment, addressing a critical area with high unmet medical need. Glioblastoma is an aggressive form of brain cancer with limited treatment options and poor prognosis. The market for glioblastoma therapies is actively seeking innovative solutions. Advancing these candidates through clinical development and securing regulatory approvals would position Telix as a leader in a challenging oncology segment, offering both precise diagnostic capabilities and potentially life-extending therapeutic interventions for patients.
• **Progression of TLX591/TLX592 for Advanced Prostate Cancer Therapy:** Beyond Illuccix, Telix is developing TLX591, a radio antibody-drug conjugate, and TLX592, a targeted alpha therapy candidate, both for prostate cancer. These therapies target later-stage or more aggressive forms of prostate cancer, offering therapeutic options where current treatments may be insufficient. The advanced prostate cancer market is large and continuously evolving, seeking more effective and targeted treatments. Successful clinical development and commercialization of these therapeutic candidates would significantly expand Telix's prostate cancer franchise, moving beyond diagnostics into direct therapeutic intervention.
• **Geographic Market Expansion and Deeper Penetration:** Telix currently operates in Australia, Belgium, Japan, Switzerland, and the United States. There is substantial opportunity to expand its commercial footprint into additional high-growth markets, particularly in Europe and Asia, where healthcare infrastructure and demand for advanced oncology treatments are increasing. Furthermore, deepening penetration within existing markets through expanded sales teams, strategic partnerships, and broader product indications could drive significant revenue growth. This geographic expansion strategy aims to leverage existing regulatory approvals and commercial infrastructure to reach a wider patient population.

What Are TLX's Competitive Advantages?

• **Specialized Radiopharmaceutical Expertise:** Deep expertise in the complex development, manufacturing, and regulatory pathways for radiopharmaceuticals, a niche area of drug development.
• **Diverse Pipeline:** A broad and advanced pipeline of both diagnostic and therapeutic candidates targeting multiple high-need oncology indications, reducing reliance on a single product.
• **Intellectual Property:** Patents and proprietary technology covering its radiopharmaceutical compounds and manufacturing processes, providing protection against generic competition.
• **Regulatory Approvals:** Existing regulatory approvals for commercial products like Illuccix in key markets, demonstrating capability to navigate complex global regulatory landscapes.
• **Integrated Approach:** Focus on 'theranostics' – combining diagnostic imaging with targeted therapy – which offers a comprehensive approach to disease management and potentially better patient outcomes.

What Does TLX Do?

Telix Pharmaceuticals Limited, founded in 2015 and headquartered in North Melbourne, Australia, is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company's core mission revolves around addressing significant unmet medical needs in cancer and rare diseases through its innovative approach to nuclear medicine. Telix has established a commercial presence in key global markets, including Australia, Belgium, Japan, Switzerland, and the United States, reflecting its international strategic focus. Its flagship commercial product, Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection), is utilized for the treatment of prostate cancer, providing a critical diagnostic tool in the management of this widespread disease. Beyond Illuccix, Telix also offers TLX66-CDx for imaging osteomyelitis, further diversifying its diagnostic portfolio. The company boasts a comprehensive and promising product pipeline, featuring several candidates in various stages of development. These include TLX591, a radio antibody-drug conjugate aimed at prostate cancer therapy; TLX250-CDx, designed for both the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; and TLX300-CDx for soft tissue sarcoma, each representing a potential advancement in targeted oncology. Additionally, Telix is developing therapeutic candidates such as TLX250 for clear cell renal cell carcinoma, TLX101 for glioblastoma, TLX66 for bone marrow conditioning, TLX300 for soft tissue sarcoma, and TLX592, a prostate cancer therapy candidate focused on targeted alpha therapy. This extensive pipeline underscores Telix's commitment to pioneering new solutions in radiopharmaceutical oncology, from early diagnosis to advanced therapeutic interventions.

What Products and Services Does TLX Offer?

• Develop and commercialize therapeutic radiopharmaceuticals for cancer and rare diseases.
• Develop and commercialize diagnostic radiopharmaceuticals for cancer and rare diseases.
• Offer Illuccix for the diagnosis and treatment management of prostate cancer.
• Provide TLX66-CDx for imaging osteomyelitis.
• Advance a pipeline of radio antibody-drug conjugates like TLX591 for prostate cancer.
• Develop dual diagnostic and therapeutic candidates such as TLX250-CDx for renal cancer.
• Focus on targeted alpha therapy candidates like TLX592 for prostate cancer.
• Conduct research and clinical trials for candidates targeting brain (glioma) cancer and soft tissue sarcoma.

How Does TLX Make Money?

• Generate revenue through the sale of commercialized radiopharmaceutical products, such as Illuccix.
• Monetize pipeline assets through successful clinical development, regulatory approval, and subsequent product launches.
• Potentially engage in licensing agreements or partnerships for specific product candidates or geographic markets.
• Invest in research and development to discover and advance new radiopharmaceutical candidates through preclinical and clinical stages.
• Establish and maintain commercial infrastructure for marketing, sales, and distribution of approved products in target regions.

What Industry Does TLX Operate In?

Telix Pharmaceuticals Limited operates within the dynamic and rapidly evolving Biotechnology industry, specifically focusing on radiopharmaceuticals for oncology and rare diseases. This niche segment of healthcare is characterized by high research and development costs, stringent regulatory pathways, and significant unmet medical needs. The global radiopharmaceutical market is experiencing growth driven by advancements in imaging technologies and the increasing adoption of targeted therapies for cancer. Telix's positioning with both diagnostic (CDx) and therapeutic radiopharmaceuticals allows it to address different stages of disease management, from early detection to advanced treatment. The competitive landscape includes established pharmaceutical giants and smaller, specialized biotech firms. Telix differentiates itself through its extensive pipeline targeting various cancers like prostate, renal, and brain cancer, leveraging proprietary technology in radio-antibody drug conjugates and targeted alpha therapy. The industry's future is shaped by innovations in precision medicine, biomarker identification, and the integration of diagnostics with therapeutics, areas where Telix is actively engaged.

Who Are TLX's Key Customers?

• Oncologists and urologists who treat patients with various cancers, particularly prostate and renal cancer.
• Nuclear medicine specialists and radiologists who utilize diagnostic imaging agents.
• Hospitals, clinics, and imaging centers that administer radiopharmaceuticals.
• Researchers and clinical trial sites involved in oncology and rare disease studies.
• Patients suffering from cancer and rare diseases who require advanced diagnostic and therapeutic options.

Company Profile

Telix Pharmaceuticals Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in North Melbourne, AU. The company is led by CEO Christian Behrenbruch. TLX has traded publicly since 2024.

Return on equity for Telix Pharmaceuticals Limited stands at 7.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.4%, showing how much profit it generates from its asset base. TLX trades at a trailing price-to-earnings ratio of 113.39, above the Healthcare sector average of ~21.50x. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.

TLX Valuation & Market Position

With a $4.03B market cap, Telix Pharmaceuticals Limited sits in the mid-cap segment of the market. Analyst price targets span from $18.00 to $18.00, with a consensus of $18.00. At the current price of $11.90, that implies approximately 51% upside potential. Relative to its peer group, TLX's quantitative score of 41/100 is below the peer average of 71/100.

Quarterly Financial Performance: Telix Pharmaceuticals Limited

Revenue for Telix Pharmaceuticals Limited came in at $691.4M during Q2 FY2026, a 11.4% improvement versus the preceding quarter. The company recorded net income of $55.5M, with diluted EPS of $0.16. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, TLX averaged $0.06 in diluted EPS.

Telix Pharmaceuticals Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 4.21 places it in the safe zone, indicating low near-term bankruptcy risk.

Telix Pharmaceuticals Limited has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 30.7% below estimates on average.

Over the past six months, Telix Pharmaceuticals Limited insiders filed 4 SEC Form 4 transactions — 1 sales and 3 purchases. On net that is roughly 68K shares acquired (about $997K) — insiders putting money in tends to read as conviction.

TLX Financials

TLX Latest News

TLX Analyst Consensus

TLX MoonshotScore

Latest Telix Pharmaceuticals Limited Analysis

Common Questions About TLX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources